BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25801713)

  • 1. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.
    Golovine K; Makhov P; Naito S; Raiyani H; Tomaszewski J; Mehrazin R; Tulin A; Kutikov A; Uzzo RG; Kolenko VM
    Cancer Biol Ther; 2015; 16(5):743-9. PubMed ID: 25801713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
    Kumar S; Agnihotri N
    Biomed Pharmacother; 2019 Jan; 109():1462-1477. PubMed ID: 30551398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
    Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Adam A; Torres D; Zhang X; Dobrolecki LE; Wei W; Lewis MT; Dave B; Chang JC; Landis MD; Creighton CJ; Mancini MA; Tweardy DJ
    Oncogene; 2015 Mar; 34(11):1341-53. PubMed ID: 24681959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma.
    Huang J; Dong B; Zhang J; Kong W; Chen Y; Xue W; Liu D; Huang Y
    Tumour Biol; 2014 Jun; 35(6):5833-43. PubMed ID: 24609899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
    Han SS; Han S; Kamberos NL
    Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP.
    Chen Y; Liu JM; Xiong XX; Qiu XY; Pan F; Liu D; Lan SJ; Jin S; Yu SB; Chen XQ
    Oncotarget; 2015 Mar; 6(8):6406-21. PubMed ID: 25788268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
    Wang F; Mao Y; You Q; Hua D; Cai D
    Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.
    Golovine KV; Makhov PB; Teper E; Kutikov A; Canter D; Uzzo RG; Kolenko VM
    Prostate; 2013 Jan; 73(1):23-30. PubMed ID: 22592999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
    Fang JD; Lee SL
    Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells.
    Seok JS; Jeong CH; Petriello MC; Seo HG; Yoo H; Hong K; Han SG
    Food Chem Toxicol; 2018 Jan; 111():9-18. PubMed ID: 29109039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway.
    Thongsom S; Suginta W; Lee KJ; Choe H; Talabnin C
    Apoptosis; 2017 Nov; 22(11):1473-1484. PubMed ID: 28913568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway.
    Gu SM; Lee HP; Ham YW; Son DJ; Kim HY; Oh KW; Han SB; Yun J; Hong JT
    Neuromolecular Med; 2018 Sep; 20(3):312-327. PubMed ID: 29802525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKCĪµ inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
    Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
    Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
    Yamauchi M; Kataoka H; Itoh H; Seguchi T; Hasui Y; Osada Y
    J Urol; 2004 Feb; 171(2 Pt 1):890-6. PubMed ID: 14713848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.